On October 31, 2023 SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, reported that it will be presenting new preclinical data at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 38th Annual Meeting taking place November 1-5, 2023 in San Diego, California (Press release, SOTIO, OCT 31, 2023, View Source [SID1234636599]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data to be presented include new preclinical results supporting the continued development of SOT201, a next-generation PD-1-inhibiting cytokine that SOTIO is progressing toward a planned first-in-human study in the second quarter of 2024. SOT201 is an antibody-cytokine fusion protein that could improve upon the efficacy of approved checkpoint inhibitors by combining PD-1 blockade with IL-15 immune stimulation in a single therapeutic construct.

Additional poster presentations at the meeting will include preclinical data on the synergistic effects of SOTIO’s IL-15 superagonist in combination with CAR T-cell therapies, as well as data on SOTIO’s IL-15 superagonist nanrilkefusp alfa.

Presentation details are as follows:

Title: "SOT201 is a novel cis-acting immunocytokine targeting IL-15Rβγ and PD-1 to reinvigorate PD-1+ tumor infiltrating lymphocytes and potentiate anti-tumor efficacy"
Number: 1087
Date: November 3, 2023
Presenter: Irena Adkins, Martin Steegmaier

Title: "Combination with IL-15Rβγ superagonist, Nanrilkefusp alfa, enhances CAR T and BOXR T cell anti-tumor activity"
Number: 815
Date: November 3, 2023
Presenter: Amy Jensen-Smith

Title: "Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumor inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers"
Number: 713
Date: November 3, 2023
Presenter: Petr Danek, Lenka Palova Jelinkova

Posters will be available after presentations conclude HERE.